Company profile
Beijing QL Biopharmaceutical
Peptide therapeutics
Privately held: no public share price · China
Assets
(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorPeptide | Obesity | |
| Phase 3 | GLP-1 receptorPeptide | Obesity | |
| Phase 2 | GLP-1 receptorPeptide | Obesity | |
| Phase 1 | FGF21/GLP-1 receptor (dual)Peptide | Obesity |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.